Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study

Giuseppe Derosa, Pietro D. Ragonesi, Amedeo Mugellini, Leonardina Ciccarelli, Robert Fogari

Research output: Contribution to journalArticle

Abstract

We evaluated the antihypertensive activity, glucose homeostasis and plasma lipid profile in patients with mild hypertension and type 2 diabetes mellitus treated by diet and exercise, and not in receipt of oral hyperglycemics, following 12-month treatment with either telmisartan or eprosartan. In this double-blind, placebo-controlled trial, 119 patients with mild essential hypertension (diastolic blood pressure [DBP] 91-104 mmHg) and type 2 diabetes were divided into three groups and randomized to receive once-daily telmisartan 40 mg, eprosartan 600 mg, or placebo for 12 months. At enrollment, patients were advised on diet (1,400-1,600 kcal/day) and exercise (physical aerobics on a bicycle for at least 30 min on 4 days each week). Compared with baseline, a significant reduction (p

Original languageEnglish
Pages (from-to)457-464
Number of pages8
JournalHypertension Research
Volume27
Issue number7
DOIs
Publication statusPublished - Jul 2004

Keywords

  • Eprosartan
  • Glucose metabolism
  • Lipid profile
  • Telmisartan
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study'. Together they form a unique fingerprint.

  • Cite this